Clinical Trial Update: Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating PDE4 inhibitor roflumilast for chronic plaque psoriasis has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Roflumilast (roflumilast)

Snippet

Sponsor: Arcutis Biotherapeutics, Inc. | Conditions: Chronic Plaque Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2022-10-18